Cibc World Markets Corp Invests $211,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Cibc World Markets Corp bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,468 shares of the company's stock, valued at approximately $211,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. FNY Investment Advisers LLC bought a new stake in Protagonist Therapeutics during the 4th quarter valued at approximately $38,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Protagonist Therapeutics during the third quarter valued at approximately $69,000. KBC Group NV grew its stake in Protagonist Therapeutics by 54.4% in the fourth quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after purchasing an additional 737 shares during the period. Nisa Investment Advisors LLC grew its stake in Protagonist Therapeutics by 10.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock worth $121,000 after purchasing an additional 295 shares during the period. Finally, Caprock Group LLC bought a new position in Protagonist Therapeutics in the fourth quarter worth $224,000. Hedge funds and other institutional investors own 98.63% of the company's stock.

Insider Activity

In related news, Director William D. Waddill sold 4,000 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the completion of the sale, the director now owns 13,130 shares in the company, valued at approximately $712,302.50. This represents a 23.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Arturo Md Molina sold 30,514 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $55.74, for a total value of $1,700,850.36. Following the completion of the transaction, the insider now directly owns 83,892 shares in the company, valued at $4,676,140.08. The trade was a 26.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,776 shares of company stock valued at $3,585,010 in the last 90 days. 5.40% of the stock is currently owned by insiders.

Remove Ads

Protagonist Therapeutics Trading Down 1.1 %

PTGX traded down $0.56 during trading on Friday, hitting $48.88. 664,503 shares of the company's stock traded hands, compared to its average volume of 796,889. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of 18.38 and a beta of 2.34. The company's 50 day simple moving average is $42.54 and its two-hundred day simple moving average is $42.87. Protagonist Therapeutics, Inc. has a 12-month low of $24.22 and a 12-month high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings data on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating the consensus estimate of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $170.64 million for the quarter, compared to analysts' expectations of $56.65 million. On average, equities analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PTGX. Wedbush reaffirmed an "outperform" rating and issued a $70.00 target price on shares of Protagonist Therapeutics in a research report on Friday. StockNews.com cut shares of Protagonist Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, December 10th. The Goldman Sachs Group decreased their target price on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating for the company in a research note on Monday, February 24th. JPMorgan Chase & Co. boosted their price target on Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 4th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research report on Friday, February 7th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $62.56.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.